Effect of Olive Leaf Extracts on Endothelial Dysfunction in Patients With Acute Coronary Syndrome

Launched by UNIVERSITY OF MONASTIR · Dec 3, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of olive leaf extract on patients who have experienced a recent acute coronary syndrome (ACS) event, which is a serious condition related to heart problems. The researchers want to see if taking olive leaf extract can improve a specific aspect of heart health called endothelial function, which is important for good blood circulation. The trial will last for 30 days, and patients will be monitored closely during this time.

To be eligible for this study, participants must be at least 18 years old and have certain heart-related changes that doctors can detect. They should not have had any recent surgeries or major heart procedures planned. Additionally, participants need to be able to understand the study and agree to take part. Throughout the trial, participants will receive guidance and support to ensure they are following the study requirements. It's important to note that this trial is not yet recruiting participants, so more information will be available as it progresses.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age over 18 years. Patients presenting with ST-segment alterations at rest, including ST elevation, with or without troponin elevation.
• • Patients who have not undergone surgery or have no additional primary percutaneous coronary intervention (P-PCI) planned within 8 weeks from the initial P-PCI.
• • Patients who provide informed consent. Patients available for and willing to adhere to follow-up procedures. Patients without significant cognitive impairment. Patients with a life expectancy of at least 2 years.
• Exclusion Criteria:
• • Severe LV hypertrophy (\>15 mm);
• • Patients with any evidence of inflammatory or malignant disease.
• • Patient having valvular heart disease, pacemaker; cardiogenic shock
• • Patient having any serious non-cardiac disease associated with a life expectancy \<1 year
• • Patients undergoing surgery within 30 days
• • Patient having gastrointestinal disorder such as Crohn's disease